Compass Therapeutics, Inc. filings document a clinical-stage oncology biopharmaceutical company developing proprietary antibody-based therapeutics. Its SEC reports include Form 8-K disclosures for operating and financial results, Regulation FD updates, clinical data presentations and other material events related to tovecimig and the broader antibody pipeline.
The company’s definitive proxy materials cover annual meeting matters, director elections and stockholder voting procedures. Filing disclosures also address governance, equity compensation, capital-structure matters, cash resources, clinical and regulatory risk areas, and the public-company controls associated with a Nasdaq-listed development-stage biotechnology issuer.
Compass Therapeutics, Inc. (CMPX) Chief Accounting Officer Neil Lerner purchased 20,000 shares of common stock at $0.92 per share on October 1, 2026. The purchase was reported as direct; no Rule 10b5-1 plan is reported. Lerner’s reported holdings after the purchase were 420,000 shares, including 62,500 unvested restricted stock units subject to service-based vesting in four equal annual installments, with the first installment vesting on January 2, 2027.
Neil Lerner, Compass Therapeutics, Inc.’s Chief Accounting Officer, reported a direct purchase of 2,500 common shares at $1.14 per share on September 24, 2026. His reported direct position after the purchase was 400,000 shares, including 62,500 unvested restricted stock units. No Rule 10b5-1 plan is reported.
Compass Therapeutics, Inc. (CMPX) reported that the FDA has recommended conducting a trial demonstrating an overall survival benefit before proceeding with a Biologics License Application (BLA) for its investigational antibody tovecimig in previously treated, advanced biliary tract cancer. Compass disagrees that a new trial is warranted and plans to further engage with the FDA while continuing BLA preparations.
The company highlights positive Phase 2/3 COMPANION-002 results, where tovecimig plus paclitaxel improved objective response rate to 18.0% versus 5.3% with paclitaxel alone and extended median progression-free survival to 4.7 versus 2.6 months, with a hazard ratio of 0.44, representing a 56% reduction in risk of disease progression. Overall survival did not reach statistical significance due to high crossover from control to tovecimig, and the safety profile was generally consistent with prior studies.
Compass Therapeutics, Inc. is reported as the issuer of common stock held by several Vivo Opportunity investment entities. Vivo Opportunity Fund Holdings, L.P. and its general partner Vivo Opportunity, LLC each report beneficial ownership of 7,207,573 shares of common stock, representing 4.0% of the class. Vivo Opportunity Cayman Fund, L.P. and its general partner Vivo Opportunity Cayman, LLC each report beneficial ownership of 549,487 shares, or 0.3% of the class. These ownership percentages are based on 180,087,915 shares of common stock outstanding as of July 28, 2026. Each reporting person has sole voting and sole dispositive power over its respective shares and reports ownership of 5% or less of the class.
State Street Corporation reported beneficial ownership of common stock of Compass Therapeutics Inc. State Street beneficially owned 9,953,653 shares of common stock, representing 5.5% of the class as of June 30, 2026. These shares are held with no sole voting or dispositive power; instead, State Street reported shared voting power over 9,687,331 shares and shared dispositive power over 9,953,653 shares. The position is held through investment management subsidiaries, including SSGA Funds Management, Inc. and several State Street Global Advisors entities.
Compass Therapeutics is a clinical-stage oncology company advancing four antibody-based programs, led by tovecimig, a DLL4/VEGF-A bispecific for biliary tract cancer. In a Phase 2/3 trial in second-line BTC, tovecimig plus paclitaxel achieved an overall response rate of 18.0% versus 5.3% with paclitaxel alone and a median progression-free survival of 4.7 months versus 2.6 months, with a hazard ratio of 0.44 and p<0.0001.
The company plans to seek FDA feedback on these data in the third quarter of 2026 ahead of a potential BLA submission and will present results at the 2026 ESMO Congress. Additional investigator-sponsored and company-sponsored studies of tovecimig are underway, while Phase 1 trials for CTX-8371 (PD-1 x PD-L1) and CTX-10726 (PD-1 x VEGF-A) continue enrolling, with more data expected in late 2026.
For the quarter ended June 30, 2026, Compass recorded a net loss of $25.154 million (or $0.13 per share), wider than a year earlier, driven by higher research and development and pre-commercialization spending. Cash, cash equivalents and marketable securities totaled $180 million, which management expects will fund operations into 2028, supporting continued clinical development and preparatory commercialization activities.
Compass Therapeutics, Inc. reported a deeper net loss while accelerating its oncology pipeline in the quarter and six months ended June 30, 2026. Net loss for the quarter was $25.2 million, or $0.13 per share, versus $19.9 million, or $0.14 per share, a year earlier. Research and development expenses rose to $19.6 million, up 19% year over year, mainly from higher spending on tovecimig, while general and administrative expenses increased to $7.4 million, up 59% on greater pre-commercialization and stock-based compensation costs. Cash and marketable securities totaled $180 million at June 30, 2026, down from $209 million at year-end 2025, and are expected to fund operations into 2028.
The lead candidate tovecimig (DLL4 x VEGF-A bispecific antibody) showed an overall response rate of 18.0% (20/111) in a Phase 2/3 biliary tract cancer study versus 5.3% for paclitaxel, with a p-value of 0.0228, and is being prepared for a potential BLA filing following FDA feedback expected in Q3 2026. The dataset was selected for an oral presentation at the 2026 ESMO Congress, and multiple investigator-sponsored trials are underway in BTC, colorectal cancer, and glioblastoma. CTX-8371 cohort expansions are enrolling patients in several tumors with additional data expected in Q4 2026, CTX-10726 has begun dosing in a multi-dose Phase 1 trial with initial data also expected in Q4 2026, and a Phase 2 trial of CTX-471 in NCAM-expressing tumors is planned to start in Q3 2026.
Compass Therapeutics furnished an updated corporate presentation outlining new clinical data and plans for its oncology pipeline, led by tovecimig for second-line biliary tract cancer (BTC). In the Phase 2/3 COMPANION-002 study, tovecimig plus paclitaxel achieved an overall response rate of 18.0% versus 5.3% with paclitaxel alone and improved median progression-free survival to 4.7 months from 2.6 months. Overall survival analysis was complicated by a 54% crossover from control to the combination, but subset analyses showed longer survival in crossover patients. The company plans an FDA meeting in Q3 2026 and a biologics license application filing in Q4 2026, targeting potential approval in 2027. Compass reports $195 million in cash and marketable securities as of Q1 2026, which it expects will fund operations into 2028 while advancing additional bispecific and CD137 programs.
Compass Therapeutics, Inc. updated its corporate governance by adopting Second Amended and Restated Bylaws, effective June 22, 2026. The new bylaws replace the prior version from July 17, 2020. They establish exclusive jurisdiction in the U.S. District Courts for the District of Delaware and District of Massachusetts for claims arising under the Securities Act of 1933.
Compass Therapeutics, Inc. reported the results of its annual stockholder meeting held on June 10, 2026. Stockholders elected Class III directors Thomas J. Schuetz and Richard S. Lindahl to serve until the 2029 annual meeting. They also ratified CohnReznick LLP as independent registered public accounting firm for the year ending December 31, 2026, with 137,896,097 votes for and 181,037 against. On a non-binding basis, stockholders approved executive compensation, with 117,963,684 votes for and 1,796,022 against, and voted to hold future advisory votes on executive compensation every year, with 118,289,260 votes favoring an annual frequency.